Observational studyClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Respiratory Syncytial Virus Hospitalizations in Adults ≥50 Years of Age and Those With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020.
Observational study in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) is a leading cause of acute respiratory illness (ARI) in older adults and those with comorbidities. Understanding disease burden could guide prevention efforts.
methodsWe performed active surveillance for RSV among adults aged ≥50 years hospitalized with ARI and adults of any age hospitalized with congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD) exacerbations from Georgia Health District 3 at 2 Atlanta hospitals during 2 respiratory seasons (2018-2019 and 2019-2020). All participants were tested for RSV using the BioFire Respiratory Panel (nasopharyngeal and oropharyngeal swabs); subsets also had serology and standard-of-care results. Annual population-based incidences of RSV-related hospitalizations were estimated by age strata and study group, adjusting for differences in sampling, diagnostic testing, and test sensitivity. Denominators for ARI incidence estimates were from the US Census. CHF and COPD denominators were limited to individuals with underlying CHF or COPD, respectively, as defined by NHANES data.
resultsOf 3090 eligible patients, 1558 were included; 757 (48.6%) had ARI, 490 (31.4%) CHF exacerbation, and 311 (20.0%) COPD exacerbation. Overall, 92 (5.9%) participants tested positive for RSV. Based on data from 2 seasons, annual population-based incidences among adults aged ≥50 years were 74 per 100 000 (95% confidence interval [CI]: 73, 77) for laboratory-confirmed RSV-related ARI hospitalizations alone, and 58% higher when including all laboratory-confirmed RSV-related hospitalizations (ARI and CHF/COPD exacerbations): 117 per 100 000 (95% CI: 114, 123).
conclusionsRSV was associated with a substantial burden of hospitalizations among adults aged ≥50 years, particularly when CHF and COPD exacerbations were included.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.